Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.5 GBX | 0.00% | -28.21% | -56.92% |
Apr. 24 | Genedrive enters clinical trial deal in US for MT-RNR1 US approval | AN |
Apr. 03 | FTSE 100 up thanks to US economic data | AN |
Business Summary
Number of employees: 43
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Diagnostics
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +12.24% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
63.6
%
| 0 | 75.5 % | 0 | 63.6 % | -5.41% |
Europe
29.1
%
| 0 | 20.4 % | 0 | 29.1 % | +60.00% |
United States
7.3
%
| 0 | 4.1 % | 0 | 7.3 % | +100.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Cheek
CEO | Chief Executive Officer | 57 | 23-09-10 |
Russell Shaw
DFI | Director of Finance/CFO | 45 | 22-04-06 |
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Gino Miele
CTO | Chief Tech/Sci/R&D Officer | 54 | 15-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Chris Yates
BRD | Director/Board Member | 50 | 18-08-21 |
Thomas Lindsay
BRD | Director/Board Member | 66 | 18-04-08 |
Russell Shaw
DFI | Director of Finance/CFO | 45 | 22-04-06 |
James Cheek
CEO | Chief Executive Officer | 57 | 23-09-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 143,141,481 | 68,602,023 ( 47.93 %) | 0 | 47.93 % |
Company contact information
Sector
Sales per Business
Sales per region
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-56.92% | 6.26M | |
-15.43% | 18.51B | |
-40.81% | 2.85B | |
+19.34% | 1.95B | |
+2.22% | 1.72B | |
+28.27% | 1.26B | |
-9.56% | 1.02B | |
-16.29% | 950M | |
+0.07% | 777M | |
-22.49% | 643M |
- Stock Market
- Equities
- GDR Stock
- Company genedrive plc